13 results about "Cardiac failures" patented technology

The invention provides compositions and methods for providing a cardioprotective effect in a subject. Specifically, the invention provides compositions and methods for treating cardiovascular ailments, for example, ischemia / reperfusion (I / R) injury, cardiac arrhythmias, oxidative stress, or cardiac failure by administering a retinoic acid receptor-beta (RARβ) agonist.

Provided are a traditional Chinese medicine composition for treating cardiorenal syndrome and cardiac failure and a method for preparing same. The traditional Chinese medicine composition is prepared from the following raw materials: 3 to 20 parts of Cinnamomi ramulus, 3 to 25 parts of Atractylodis macrocephalae rhizoma, 3 to 25 parts of Jujubae fructus, 6 to 45 parts of Astragali radix, 2 to 20 parts of Panacis majoris rhizoma, 3 to 30 parts of Paeoniae rubra radix, 6 to 25 parts of Spatholobi caulis, 6 to 25 parts of Ginkgo folium, 6 to 35 parts of Poria, 3 to 20 parts of Zingiberis rhizoma recens, 2 to 25 parts of Citri fructus, 2 to 15 parts of Nigellae semen, 2 to 20 parts of Inulae flos, and 3 to 25 parts of Alismatis rhizoma.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

To provide a method for treating a subject having cardiac failure.SOLUTION: A method includes administering an initial dose of cardiac sarcomere activator (CSA) to a subject for a first period, and subsequently, administering a dose of CSA based on the plasma concentration of CSA in the subject at the end of the first period to the subject.SELECTED DRAWING: None

The invention relates to the technical field of metabolic markers, in particular to application of metabolic markers in preparation of products for detecting or diagnosing coronary heart disease adverse cardiovascular events and a construction method of a coronary heart disease adverse cardiovascular event diagnosis model. The coronary heart disease adverse cardiovascular event product is used for detecting or diagnosing coronary heart disease cardiovascular death events and / or coronary heart disease heart failure events. According to the application, the risks of death events and heart failure events of the coronary heart disease patients are predicted by using the specific differential metabolites, dense monitoring can be performed on the coronary heart disease patients, and effective customized treatment guidance is provided for clinicians.

The present disclosure relates to compounds of Formula (I′):and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.

The present invention aims to provide a medicament capable of treating and / or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1):wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and / or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

The present disclosure relates to compounds of Formula (I’): , and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.

The present invention aims to provide a medicament capable of treating and / or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1):wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and / or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skid: disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

The present invention aims to provide a medicament capable of treating and / or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1):wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the compound, for the prophylaxis and / or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

This health management system executes a bathing determination process, a first acquisition process, a second acquisition process, a pulse data acquisition process, a determination process, and an output process. The bathing determination process is for determining bathing and bathing completion of a subject. The first acquisition process is for acquiring, as a first oxygen saturation level, the result of measurement of the blood oxygen saturation level of the subject during a first measurement period. The second acquisition process is for acquiring, as a second oxygen saturation level, the blood oxygen saturation level of the subject during a second measurement period. The pulse data acquisition process is for acquiring the pulse rate of the subject. The determination process is for making a determination related to the state of health based cardiac failure in the subject, on the basis of the value of the first oxygen saturation level, the value of the second oxygen saturation level, and a change in the pulse rate. The output process is for outputting the result of determination in the determination process.

A detection apparatus includes a biosignal acquisition unit configured to acquire a biosignal of a user, and a controller. The controller is configured to calculate one or more parameter values related to breathing of the user based on the biosignal acquired from the biosignal acquisition unit, and detect a presence of a symptom of aggravation of cardiac failure in the user when a calculated parameter value in which a cumulative value of previous day difference data has exceeded a predetermined threshold is present, among the calculated parameter values.

The present disclosure relates to compounds of Formula (I′):and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin receptor activity and may be used in the treatment of disorders in which orexin receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anaesthesia.